ADXN
The numbers aren’t pretty, but they’re not one-note either
Addex Therapeutics came out with first-half results showing a wider net loss, which is never exactly the kind of headline that makes investors high-five their screens. But there’s a small silver lining: operating loss narrowed from a year ago, helped by lower research and development expenses.
Why the market might still peek twice
For a biotech like Addex, the story is rarely just the income statement. The company also said it advanced its GABAB PAM cough program, which matters because pipeline progress is the thing that can turn a sleepy quarterly update into a real catalyst. In other words: the red ink is bad, but the science treadmill is still moving.
What you should watch next
If you’re watching ADXN, the key question isn’t just whether losses shrink — it’s whether Addex can keep advancing its pipeline without burning through cash like a teenager with a fresh debit card.
- Lower R&D spending helped operating loss narrow
- Net loss still widened on the half-year
- GABAB PAM cough program advanced, keeping the biotech narrative alive
Big picture: for small-cap drug developers, investors usually forgive losses if the pipeline keeps producing breadcrumbs of momentum. That’s the real scoreboard here.